WTZ Netzwerkpartner Münster

NEUE WEBSITE

Publikationen

Hier finden Sie eine Auswahl aktueller Publikationen von Forschenden
des WTZ Münster.

Publikationen 2021

  • Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. Larrue C, Guiraud N, Mouchel PL, Dubois M, Farge T, Gotanègre M, Bosc C, Saland E, Nicolau-Travers ML, Sabatier M,  Serhan N,  Sahal A,  Boet E,  Mouche S,  Heydt Q,  Aroua N,  Stuani L,  Kaoma T,  Angenendt L,  Mikesch JH,  Schliemann C,  Vergez F,  Tamburini J,  Récher C,  Sarry JE  Nat Commun
  • Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Frontzek F,  Staiger AM,  Zapukhlyak M,  Xu W,  Bonzheim I,  Borgmann V,  Sander P,  Baptista MJ,  Heming JN,  Berning P,  Wullenkord R,  Erdmann T,  Lutz M,  Veratti P,  Ehrenfeld S,  Wienand K,  Horn H,  Goodlad JR,  Wilson MR,  Anagnostopoulos I,  Lamping M,  Gonzalez-Barca E,  Climent F,  Salar A,  Castellvi J,  Abrisqueta P,  Menarguez J,  Aldamiz T,  Richter J,  Klapper W,  Tzankov A,  Dirnhofer S,  Rosenwald A,  Mate JL,  Tapia G,  Lenz P,  Miething C,  Hartmann W,  Chapuy B,  Fend F,  Ott G,  Navarro JT,  Grau M,  Lenz G  Nat Commun
  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ, VISION Investigators   N Engl J Med
  • Donor cell memory confers a metastable state of directly converted cells. Kim KP, Li C, Bunina D, Jeong HW, Ghelman J, Yoon J, Shin B, Park H, Han DW, Zaugg JB, Kim J, Kuhlmann T, Adams RH, Noh KM, Goldman SA, Schöler HR Cell Stem Cell. 2021 Jul 1;28(7):1291-1306.e10. doi: 10.1016/j.stem.2021.02.023. Epub 2021 Apr 12.
  • Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS). Casali PG, Le Cesne A, Velasco AP, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR,  Italiano A,  Gelderblom H,  Penel N,  Hartmann JT,  Duffaud F,  Goldstein D,  Martin-Broto J,  Gronchi A,  Wardelmann E,  Marréaud S,  Zalcberg JR,  Litière S,  Blay JY. Ann Oncol
  • Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Gaspar N, Venkatramani R,  Hecker-Nolting S,  Melcon SG,  Locatelli F,  Bautista F,  Longhi A,  Lervat C,  Entz-Werle N,  Casanova M,  Aerts I,  Strauss SJ,  Thebaud E,  Morland B,  Nieto AC,  Marec-Berard P,  Gambart M,  Rossig C,  Okpara CE,  He C,  Dutta L,  Campbell-Hewson Q  Lancet Oncol
  • 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lehrnbecher T,  Averbuch D,  Castagnola E,  Cesaro S,  Ammann RA,  Garcia-Vidal C,  Kanerva J,  Lanternier F,  Mesini A,  Mikulska M,  Pana D,  Ritz N,  Slavin M,  Styczynski J,  Warris A,  Groll AH,  8th European Conference on Infections in Leukaemia   Lancet Oncol
  • Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Scheller M, Ludwig AK, Goellner S, Rohde C,  Kraemer S,  Staeble S,  Janssen M,  Mueller JA,  He LXZ,  Baumer N,  Arnold C,  Gerss J,  Schoenung M,  Thiede C,  Niederwieser C,  Niederwieser D,  Serve H,  Berdel WE,  Thiem U,  Hemmerling I,  Leuschner F,  Plass C,  Schlesner M,  Zaugg J,  Milsom MD,  Trumpp A,  Pabst C,  Lipka DB,  Muller-Tidow C  Nat. Cancer
  • The Burden of Survivorship on Hematological Patients-Long-Term Analysis of Toxicities after Total Body Irradiation and Allogeneic Stem Cell Transplantation. Oertel M, Martel J, Mikesch JH, Scobioala S, Reicherts C, Kröger K, Lenz G, Stelljes M, Eich HT. Cancers (Basel). 2021 Nov 11;13(22):5640. doi: 10.3390/cancers13225640.
  • Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas. Schliemann C, Hemmerle T, Berdel AF, Angenendt L, Kerkhoff A, Hering JP, Heindel W, Hartmann W, Wardelmann E, Chawla SP, de Braud F, Lenz G, Neri D, Kessler T, Berdel WE. Eur J Cancer. 2021 Jun;150:143-154. doi: 10.1016/j.ejca.2021.03.038. Epub 2021 Apr 23.
  • Imaging temozolomide-induced changes in the myeloid glioma microenvironment. Foray C, Valtorta S, Barca C, Winkeler A, Roll W, Müther M, Wagner S, Gardner ML, Hermann S, Schäfers M, Grauer OM, Moresco RM, Zinnhardt B, Jacobs AH. Theranostics. 2021 Jan 1;11(5):2020-2033. doi: 10.7150/thno.47269. eCollection 2021.
  • WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer. Menck K, Heinrichs S, Wlochowitz D, Sitte M, Noeding H, Janshoff A, Treiber H, Ruhwedel T, Schatlo B, von der Brelie C, Wiemann S, Pukrop T, Beißbarth T, Binder C & Bleckmann A. J Exp Clin Cancer Res 40, 395 (2021).
  • Establishment of a Palliative Care Consultation Service (PCCS) in an Acute Hospital Setting. Engel PT, Thavayogarajah T, Görlich D, Lenz P. Int J Environ Res Public Health. 2020 Jul 10;17(14):4977. doi: 10.3390/ijerph17144977.
  • Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma. Knörr F, Zimmermann M, Attarbaschi A, Kabíčková E, Maecker-Kolhoff B, Ruf S, Kühnle I, Ebinger M, Garthe AK, Simonitsch-Klupp I, Oschlies I, Klapper W, Burkhardt B, Woessmann W. Haematologica. 2021 Dec 1;106(12):3232-3235. doi: 10.3324/haematol.2021.278971.
  • An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma. Albert TK, Interlandi M, Sill M, Graf M, Moreno N, Menck K, Rohlmann A, Melcher V, Korbanka S, Meyer Zu Hörste G, Lautwein T, Frühwald MC, Krebs CF, Holdhof D, Schoof M, Bleckmann A, Missler M, Dugas M, Schüller U, Jäger N, Pfister SM, Kerl K. Neuro Oncol. 2021 Apr 12;23(4):586-598. doi: 10.1093/neuonc/noaa254.
  • The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke). Barca C, Foray C, Hermann S, Herrlinger U, Remory I, Laoui D, Schäfers M, Grauer OM, Zinnhardt B, Jacobs AH. Front Immunol. 2021 Dec 7;12:787307. doi: 10.3389/fimmu.2021.787307. eCollection 2021.
  • 5-Aminolevulinic Acid-Induced Porphyrin Contents in Various Brain Tumors: Implications Regarding Imaging Device Design and Their Validation. Suero Molina E, Kaneko S, Black D, Stummer W. Neurosurgery. 2021 Nov 18;89(6):1132-1140. doi: 10.1093/neuros/nyab361.
  • The Lymph-Sparing Quotient: A Retrospective Risk Analysis on Extremity Radiation for Soft Tissue Sarcoma Treatment. Sarif I, Elsayad K, Rolf D, Kittel C, Gosheger G, Wardelmann E, Haverkamp U, Eich HT. Cancers (Basel). 2021 Apr 27;13(9):2113. doi: 10.3390/cancers13092113.
  • Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy. Seifert R, Kessel K, Schlack K, Weckesser M, Kersting D, Seitzer KE, Weber M, Bögemann M, Rahbar K. Theranostics. 2021 Jul 13;11(17):8143-8151. doi: 10.7150/thno.60222. eCollection 2021.
  • The genetic landscape of choroid plexus tumors in children and adults. Thomas C, Soschinski P, Zwaig M, Oikonomopoulos S, Okonechnikov K, Pajtler KW, Sill M, Schweizer L, Koch A, Neumann J, Schüller U, Sahm F, Rauschenbach L, Keyvani K, Proescholdt M, Riemenschneider MJ, Segewiß J, Ruckert C, Grauer O, Monoranu CM, Lamszus K, Patrizi A, Kordes U, Siebert R, Kool M, Ragoussis J, Foulkes WD, Paulus W, Rivera B, Hasselblatt M. Neuro Oncol 2021 Apr 12;23(4):650-660. doi: 10.1093/neuonc/noaa267.
  • Imaging temozolomide-induced changes in the myeloid glioma microenvironment. Foray C, Valtorta S, Barca C, Winkeler A, Roll W, Müther M, Wagner S, Gardner ML, Hermann S, Schäfers M, Grauer OM, Moresco RM, Zinnhardt B, Jacobs AH. Theranostics. 2021 Jan 1;11(5):2020-2033. doi: 10.7150/thno.47269. eCollection 2021.
  • CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. Klümper N, Ralser DJ, Zarbl R, Schlack K, Schrader AJ, Rehlinghaus M, Hoffmann MJ, Niegisch G, Uhlig A, Trojan L, Steinestel J, Steinestel K, Wirtz RM, Sikic D, Eckstein M, Kristiansen G, Toma M, Hölzel M, Ritter M, Strieth S, Ellinger J, Dietrich D. J Immunother Cancer. 2021 Aug;9(8):e002949. doi: 10.1136/jitc-2021-002949.
  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. Motzer R,  Alekseev B,  Rha SY,  Porta C,  Eto M,  Powles T,  Grünwald V,  Hutson TE,  Kopyltsov E,  Méndez-Vidal MJ,  Kozlov V,  Alyasova A,  Hong SH,  Kapoor A,  Alonso Gordoa T,  Merchan JR,  Winquist E,  Maroto P,  Goh JC,  Kim M,  Gurney H,  Patel V,  Peer A,  Procopio G,  Takagi T,  Melichar B,  Rolland F,  De Giorgi U,  Wong S,  Bedke J,  Schmidinger M,  Dutcus CE,  Smith AD,  Dutta L,  Mody K,  Perini RF,  Xing D,  Choueiri TK,  CLEAR Trial Investigators. N Engl J Med
  • The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. de Jong MME,  Kellermayer Z,  Papazian N,  Tahri S,  Hofste Op Bruinink D,  Hoogenboezem R,  Sanders MA,  van de Woestijne PC,  Bos PK,  Khandanpour C,  Vermeulen J,  Moreau P,  van Duin M,  Broijl A,  Sonneveld P,  Cupedo T. Nat Immunol. 2021 Jun;22(6):769-780. doi: 10.1038/s41590-021-00931-3. Epub 2021 May 20.
  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Powles T,  Csőszi T,  Özgüroğlu M,  Matsubara N,  Géczi L,  Cheng SY,  Fradet Y,  Oudard S,  Vulsteke C,  Morales Barrera R,  Fléchon A,  Gunduz S,  Loriot Y,  Rodriguez-Vida A,  Mamtani R,  Yu EY,  Nam K,  Imai K,  Homet Moreno B,  Alva A,  KEYNOTE-361 Investigators Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26.